Identification of a Recurrent STRN/ALK Fusion in Thyroid Carcinomas
Authors:
Open Access
- 27 January 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (1) , e87170
Abstract
Thyroid carcinoma is the most common endocrine malignant tumor and accounts for 1% of all new malignant diseases. Among all types and subtypes of thyroid cancers that have been described so far, papillary thyroid carcinoma is the most frequent. The standard management treatment of these tumors consists of surgery, followed by radioiodine treatment in case of high risk of relapse. The most aggressive forms are commonly treated by chemotherapy, radiotherapy or experimental drug testing. We recently reported the case of a patient presenting an anaplastic thyroid carcinoma with lung metastases. Fluorescence in situ hybridization analysis allowed us to detect a rearrangement of the anaplastic lymphoma kinase (ALK) gene in both tumors. The patient was treated with crizotinib and presented an excellent drug response. We present here the subsequent investigations carried out to further characterize this genetic alteration and to assess the prevalence of ALK rearrangements in thyroid lesions. High resolution array-comparative genomic hybridization data complemented by RT-PCR and sequencing analyses, allowed us to demonstrate the presence of a STRN/ALK fusion. The STRN/ALK transcript consisted of the fusion between exon 3 of STRN and exon 20 of ALK. Subsequent screening of 75 various thyroid tumors by RT-PCR revealed that 2 out of 29 papillary thyroid carcinomas exhibited the same fusion transcript. None was detected in other types of malignant or benign thyroid lesions analyzed. These findings could pave the way for the development of new targeted therapeutic strategies in the treatment of papillary thyroid carcinomas and point to ALK inhibitors as promising agents that merit rapid evaluation.Keywords
This publication has 25 references indexed in Scilit:
- ALK-Rearranged Lung Cancer in Chinese: A Comprehensive Assessment of Clinicopathology, IHC, FISH and RT-PCRPLOS ONE, 2013
- Rearranged Anaplastic Lymphoma Kinase ( ALK ) Gene in Adult-Onset Papillary Thyroid Cancer Amongst Atomic Bomb SurvivorsThyroid®, 2012
- Scaffolding proteins mediating membrane-initiated extra-nuclear actions of estrogen receptorSteroids, 2011
- A Novel, Highly Sensitive Antibody Allows for the Routine Detection ofALK-Rearranged Lung Adenocarcinomas by Standard ImmunohistochemistryClinical Cancer Research, 2010
- New therapeutic approaches for metastatic thyroid carcinomaThe Lancet Oncology, 2007
- Follicular thyroid carcinoma: Histology and prognosisCancer, 2004
- Papillary and Follicular Thyroid CarcinomaNew England Journal of Medicine, 1998
- Role of the Nucleophosmin (NPM) Portion of the Non-Hodgkin’s Lymphoma-Associated NPM-Anaplastic Lymphoma Kinase Fusion Protein in OncogenesisMolecular and Cellular Biology, 1997
- Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's LymphomaScience, 1994
- Oncogenic activation of tyrosine kinasesCurrent Opinion in Genetics & Development, 1994